Letters A pill too hard to follow

Compulsory licences for direct acting antiviral drugs for hepatitis C

BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5314 (Published 05 October 2016) Cite this as: BMJ 2016;355:i5314
  1. Adriano Cattaneo, epidemiologist (retired)1,
  2. Gavino Maciocco, lecturer in public health2
  1. 1Androna San Fortunato 8, 34136 Trieste, Italy
  2. 2University of Florence Medical School, Florence, Italy
  1. adriano.cattaneo{at}gmail.com

In Italy, the decision to ration treatment with direct acting drugs against hepatitis C virus was taken behind closed doors by the Ministry of Health. A 12 week course of treatment with sofosbuvir costs €41 000 (£35 500; $46 000), and the ministry has so far authorised 55 000 treatments—about 5% of the estimated need. The reason …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe